Prescription Pharmaceuticals (Rx)
New mechanisms, regulated pathways
We bring emerging mechanisms of action into markets ready to adopt them, developed to full CTD dossier standard with the clinical substantiation the indication demands.
Pharmaceutical Innovation Platform · Latin America
Innovating to create value.
We turn frontier science into brands that lead their category — from concept through registration to the shelf, across every regulatory class in prescription and consumer health.
Lead the way™
The opportunity is not incremental. It is structural.
The Opportunity
Latin America rewards those who arrive with the right architecture.
The region concentrates more than six hundred million people and is undergoing a structural shift in access to health. Demand is widening across the full spectrum — from everyday care to specialised therapy — while regulatory frameworks converge toward international standards. The category positions that will define the next decade are being built now.
Demand across the full spectrum
From everyday self-care to specialty therapies, the region is widening access at every level of complexity.
Regulatory convergence
Frameworks across the region are aligning with international standards. The bar rises and the ground clears for those able to meet it.
Categories still forming
Much of the market has no consolidated positions. Where a category is not yet defined, it is defined by whoever arrives with the right architecture.
Between opportunity and leadership there is a distance.
The Conversion Gap
Frontier science is abundant. The capability to convert it into a category is not.
Between a promising molecule and a brand leading its category at mass-consumption scale sits a sequence that very few organisations hold end to end. Each link is specialised. Held separately, they accumulate cost and time. Held together, they compress both.
Proprietary development end-to-end
Science that becomes an owned asset, built from its origin to scale, not a licensed input.
Classification and claim strategy
The regulatory route determines the commercial ceiling before a single filing is made.
Market-by-market end-to-end execution
Every authority in the region applies its own standard of evidence, dossier and review rhythm.
Architecture for mass consumption
Designed from the first formulation for the scale of the category it intends to lead.
XANUM operates across that entire sequence.
The Gateway
The gateway to the best innovation in every category we enter.
We do not select categories in order to occupy them. We enter where the science is moving, and we bring the frontier with us — engineered from the first formulation for mass-consumption scale.
Consumer Healthcare (OTC)
Pharmaceutical substance at everyday scale
The highest-volume categories in the region. We enter them with pharmaceutical-grade substantiation and the claim architecture that unlocks mass adoption.
Bioactive Natural Medicines
Botanical tradition, pharmaceutical rigour
The category legitimising fastest in the region. We bring characterised actives, standardised extracts and validated delivery to a space that has historically lacked them.
Nutritional Supplements
From commodity to branded platform
We build nutraceutical platforms with substantiated claims and formats designed around real consumption occasions — the shift from undifferentiated supplement to category-defining brand.
Substance-Based Medical Devices
A classification frontier few navigate
Devices acting by physical or physicochemical mechanism — a pathway that unlocks claims unavailable elsewhere, and among the most demanding to document. We navigate it.
Dermocosmetics & Nutricosmetics
Where clinical efficacy meets the beauty economy
Dermatological substantiation delivered with consumer-grade sensory experience — the convergence of two of the largest consumer categories in the region.
Advanced Modality
Peptide Therapeutics
The modality reshaping metabolic health
Synthetic peptide assets for metabolic and specialty indications, developed exclusively through regulated pathways: GMP-qualified API sourcing and supplier qualification, full characterisation and impurity profiling, and a stability and delivery strategy appropriate to the modality.
Forms we turn into advantage
Format is not a packaging decision: it defines the occasion of use, treatment adherence and the price the category will bear. We select each form for the advantage it opens.
Eleven ways to reach the consumer. Each chosen for the advantage it opens, never by default.
The discipline behind the portfolio
Three decisions that turn every asset into a category position, not just another product.
Claim architecture
The regulatory class is selected for the strongest defensible claim it unlocks for each asset, not for the default pathway.
Category laddering
Assets are tiered and sequenced so the portfolio expands the category instead of competing with itself.
Defensible differentiation
Every concept holds proprietary ground across formulation, method, delivery system and brand architecture.
We do not enter a category to participate in it. We enter to decide where it goes next.
The gateway rests on a discipline.
Innovation Leadership
Innovation is our operating standard, not a department.
Our Innovation Catalyst philosophy and Forward Solutions methodology exist for one purpose: to convert an opportunity into a brand that leads its category — a distinctive concept with high intellectual property content, supported by rigorous scientific evidence, high-quality production and a communication strategy built to lead.
- 01
Explore opportunities
Identify high-impact space where science, pathway and demand converge.
- 02
Develop added value
A distinctive concept with defensible intellectual property.
- 03
Technical dossier and evidence
Scientific substantiation and proprietary studies where required.
- 04
Registration and production
Health authorisation and high-standard manufacturing.
- 05
Market strategy
Positioning and communication designed to lead the category.
Science does not reach the consulting room on its own.
Commercial Architecture
A registration is permission. Category leadership is built after it.
The distance between an approved asset and a brand that leads its category is covered by three disciplines that rarely travel together: design of international standard, strategy delivered ready to execute, and a field force with scientific command.
Design that earns its place on the shelf
Brand architecture, naming, visual identity and structural packaging developed to international standard, against the category the asset intends to lead.
Strategy delivered ready to execute
Positioning, claim hierarchy, launch sequencing, channel and trade architecture, and the complete communication system, handed over finished.
The medical visit is where the science lands
In prescription and pharmacy channels, the brand is decided in front of the healthcare professional. Those teams are trained by the same team that built the dossier.
The enablement system
Virtual academy
Continuous remote training across every market.
Scientific narrative
Mechanism, evidence and clinical argument in a single structure.
Objection handling
Prepared responses to the specialist's question.
Field materials
Field materials built from the source dossier.
What is handed over is not a product, but a brand a team knows how to defend.
Evidence earns the right to scale. Scale is where value is created.
The Partnership Equation
Originated innovation. Shared scale.
We originate the science and turn it into assets designed to scale. Our partners contribute the commercial reach that turns a category-defining asset into a category-defining brand.
Innovation of exclusive origin
We originate the science behind every asset: formulations, methods, delivery systems and brand architecture. For our partners, that means entering a category on exclusive, defensible ground — not undifferentiated space — with rights defined together.
Protection defined line by line
Patent filing, trade secret, regulatory exclusivity or brand architecture: the route is selected according to where the defensible ground sits for each line.
Engineered for mass consumption
Every asset is built from the first formulation for the scale of the category it intends to lead.
Reach as the multiplier
A partner's commercial reach converts a proprietary asset into regional or global share. Originated science and commercial scale: that is the equation.
Models of Collaboration
Forms of collaboration.
An international asset enters the region
We take responsibility for classification strategy, dossier, registration, production and market entry across the region.
Developed platforms that cross into other markets
Developed concepts and proprietary formulations, ready to be adapted and launched under a partner's commercial reach.
New assets built jointly
Joint development programmes with intellectual property structured to reflect each party's contribution.
End-to-end partnership
From concept to point of sale, under a single accountable counterpart in every market.
We can enter at any stage of the development cycle — beginning, middle or final.
TRACK RECORD
What we have already built.
Four programmes, across four distinct regulatory classes.
Challenge
Develop a patented pharmaceutical asset for an occasion the category had never addressed with regulated science.
Outcome
A protected formulation supported by its own technical dossier, launched into a category created rather than entered.
Challenge
Build proprietary territory in a mature respiratory category, where the same active competes on price and no brand holds a differentiated position.
Outcome
A superior-absorption architecture deployed across four formats and three age segments — from adults to children of two — resolving the sensory barrier that has historically limited treatment adherence.
Challenge
Bring a phytotherapeutic portfolio to market with delivery technology and scientific substantiation the category had lacked.
Outcome
A range built on characterised actives and validated delivery, substantiated for the claims it carries.
Challenge
Build a probiotic spore portfolio with genuine added value across multiple technology tiers.
Outcome
A tiered platform spanning several formulations, each occupying distinct commercial territory within the same category.
Governance & Assurance
Delegating execution should never mean surrendering control.
Standards, oversight and exposure are defined before starting, not when the question arises.
Quality systems at the most demanding standard
Manufacturing executed to GMP standard with documented supplier qualification, specification control and full batch traceability. The most demanding quality standard defines the operating level.
Defined decision rights
Governance structure agreed at the outset: what is decided jointly, what is decided locally, and what escalates. No ambiguity when it matters.
Full visibility, market by market
Regulatory status, filing progress and post-authorisation obligations reported transparently across every market in the programme.
Reputational protection as a discipline
Pharmacovigilance, compliance and audit readiness are maintained continuously — not assembled when an inspection is announced.
A partner's reputation is protected as our own, because in this region it is.
Executed market by market, across a region that consumes at scale.
Regional Reach
A region that consumes at scale.
Not a single market and not a pilot, but a region whose pharmacy channel moves consumer-goods volume with pharmaceutical credibility — with the infrastructure and market-by-market knowledge already in place.
+11
markets with regional presence
+15
years of trajectory in the sector
One platform, the entire region
- Mexico
- Central America
- Caribbean
- Colombia
- Ecuador
- Peru
- Andean Region
- Southern Cone
- Brazil
Nine regional fronts covering more than eleven markets with an active health registration, product in market or live commercial agreement.
Corporate Standing
A corporation built for global scale.
We operate as a corporation legally constituted in three strategic jurisdictions — the institutional base for collaborating with any company in the world.
United States
Constituted entity — vehicle for the United States market.
Latin America
Parent operation and base for development, production and regional commercialisation.
Spain
Constituted presence — gateway to the European market.
The Invitation
Let’s create value together.
Innovation is not simply doing something different: it is bringing people what they are genuinely looking for. Winning Latin America is built jointly.
Start the conversation
Contact us
The conversation starts here.
A brief description of the interest is enough. The XANUM team replies directly and in confidence.
All communication is confidential.